| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenue | 11,734 | 2,920 | 9,977 | 2,676 |
| Research and development | 58,426 | 71,029 | 59,058 | 48,265 |
| General and administrative | 18,859 | 18,493 | 21,123 | 18,257 |
| Total operating expenses | 77,285 | 89,522 | 80,181 | 66,522 |
| Loss from operations | -65,551 | -86,602 | -70,204 | -63,846 |
| Gain (loss) on extinguishment of debt | - | - | - | -954 |
| Interest and other income | 6,700 | 7,473 | 8,414 | 10,583 |
| Interest expense | 44 | 54 | 51 | 33 |
| Total other income, net | 6,656 | 7,419 | 8,363 | 9,596 |
| Net loss before income tax provision | -58,895 | -79,183 | -61,841 | -54,250 |
| Provision for (benefit from) income taxes | 205 | -231 | -1,087 | -3,448 |
| Net loss | -59,100 | -78,952 | -60,754 | -50,802 |
| Foreign currency translation adjustment | -108 | -1,902 | -1,580 | -2,093 |
| Total comprehensive loss | -59,208 | -80,854 | -62,334 | -52,895 |
| Earnings per share, basic | -0.85 | -1.14 | -0.88 | -0.74 |
| Earnings per share, diluted | -0.85 | -1.14 | -0.88 | -0.74 |
| Weighted average number of shares outstanding, basic | 69,303,746 | 69,252,009 | 69,196,945 | 68,988,858 |
| Weighted average number of shares outstanding, diluted | 69,303,746 | 69,252,009 | 69,196,945 | 68,988,858 |
BICYCLE THERAPEUTICS PLC (BCYC)
BICYCLE THERAPEUTICS PLC (BCYC)